Man-o-Man, lots of negative Nancy’s coming out o
Post# of 405
Posted On: 08/27/2016 12:39:32 AM
Man-o-Man, lots of negative Nancy’s coming out of the woodwork today on other message boards. As an INNV long, let me attempt to “change the tide” a wee bit by stating the following:
FACT - Not too long ago this stock was trading at 8 cents with a tad less than $1M in Revenue with ~ 55M o/s. Well, we know that Mgt. has stated numerous times that they are tracking towards the high end of their 2016 revenue guidance – which is $5M. Product was being distributed in 28 countries five months ago and now they are in 60+...do you really think they are done expanding? Think about the sheer number in their customer base now vs. then & the many cross-sale opportunities that BH brings into the mix.
We also know that their recent Asian deal and especially the India ruling/KLAB’s contract will likely bring in another $2.5 – 3M combined. In addition, we heard from Mgt that 3 new products WILL be launched IN 2016 which should bring in an additional $4M to the bottom line. Plus, we know that Vesele is selling very well and gaining more traction and INNV has plenty of cash on hand from recent fundraising/warrant exercise. (well-funded through Q3 of 2017).
Folks, their ANDA application is coming up on 2 years AND the FDA has come under fire THIS WEEK in regards to the EpiPen pricing saga. This matter is causing heavyweights (ex: Larry Kudlow) to urge the FDA to approve more generics, more quickly, in an effort to create competition and lower prices. I have been watching it every day for 3 days on CNBC at lunchtime and the anchors really hammered the FDA and their role. Now, please keep in mind, prescription Fluticare is already very safe and is the #1 prescribed nasal allergy relief medicine. WHY wouldn’t it be approved for OTC as the last thing the FDA needs is more scrutiny / bad press?
So HC – make your friggin point already...let’s work with some NUMBERS:
Trading 8 cents for a long time w/ $1M rounded up in Revs. Soon we will have over $5M THIS YEAR ALONE and another $7M+ added to that in 2017. Come year end 2017 revenues should be $12-13M WITHOUT Fluticare. With it, we are conservatively looking at $13M in US sales and another $5-6M from Int’l sales. It is not out of the realm of possibility that Fluticare approval could ADD another $19M on top of the $12M to finish 2017 around $31M in total. BUT let’s NOT even figure Fluticare in – let’s just go with the $12M and assume very little revenue growth on their existing Beyond Human product line (which is highly unlikely as sales have been increasing YOY)
$12M x .08 = 96 cents Divided by 2 (as we do have almost DOUBLE the amount of o/s) = 48 cents. THAT IS THE LOW END - WITH NO FLUTICARE IMO. With it, you are looking at say 30M x .08 Divided by 2 = $1.20. I happen to think that there is a better than 75% chance of approval since it is an ANDA application, so Mr. Market should really factor in some sort of a Premium in anticipation of that. So WHY do some folks still think this is going to sub 20 cents when it should be approaching 50 cents and headed above $1 with FDA approval and short covering? All serious comments encouraged and welcomed as the sky is NOT FALLING IMO. Profitability comes by Spring of 2017 – ahead of schedule!!
- This OTC ticker has a proven winner at the helm in Dr. D, is cash flow positive, and has a major game-changing product ready for approval which can happen any day now. IF You ain’t in when positive news hits, you likely miss dollar-land people with a potential buyout inside of 2 years.
* GLTA and try some products (order online) – they WORK ! Also, review post #39 and please do your part
FACT - Not too long ago this stock was trading at 8 cents with a tad less than $1M in Revenue with ~ 55M o/s. Well, we know that Mgt. has stated numerous times that they are tracking towards the high end of their 2016 revenue guidance – which is $5M. Product was being distributed in 28 countries five months ago and now they are in 60+...do you really think they are done expanding? Think about the sheer number in their customer base now vs. then & the many cross-sale opportunities that BH brings into the mix.
We also know that their recent Asian deal and especially the India ruling/KLAB’s contract will likely bring in another $2.5 – 3M combined. In addition, we heard from Mgt that 3 new products WILL be launched IN 2016 which should bring in an additional $4M to the bottom line. Plus, we know that Vesele is selling very well and gaining more traction and INNV has plenty of cash on hand from recent fundraising/warrant exercise. (well-funded through Q3 of 2017).
Folks, their ANDA application is coming up on 2 years AND the FDA has come under fire THIS WEEK in regards to the EpiPen pricing saga. This matter is causing heavyweights (ex: Larry Kudlow) to urge the FDA to approve more generics, more quickly, in an effort to create competition and lower prices. I have been watching it every day for 3 days on CNBC at lunchtime and the anchors really hammered the FDA and their role. Now, please keep in mind, prescription Fluticare is already very safe and is the #1 prescribed nasal allergy relief medicine. WHY wouldn’t it be approved for OTC as the last thing the FDA needs is more scrutiny / bad press?
So HC – make your friggin point already...let’s work with some NUMBERS:
Trading 8 cents for a long time w/ $1M rounded up in Revs. Soon we will have over $5M THIS YEAR ALONE and another $7M+ added to that in 2017. Come year end 2017 revenues should be $12-13M WITHOUT Fluticare. With it, we are conservatively looking at $13M in US sales and another $5-6M from Int’l sales. It is not out of the realm of possibility that Fluticare approval could ADD another $19M on top of the $12M to finish 2017 around $31M in total. BUT let’s NOT even figure Fluticare in – let’s just go with the $12M and assume very little revenue growth on their existing Beyond Human product line (which is highly unlikely as sales have been increasing YOY)
$12M x .08 = 96 cents Divided by 2 (as we do have almost DOUBLE the amount of o/s) = 48 cents. THAT IS THE LOW END - WITH NO FLUTICARE IMO. With it, you are looking at say 30M x .08 Divided by 2 = $1.20. I happen to think that there is a better than 75% chance of approval since it is an ANDA application, so Mr. Market should really factor in some sort of a Premium in anticipation of that. So WHY do some folks still think this is going to sub 20 cents when it should be approaching 50 cents and headed above $1 with FDA approval and short covering? All serious comments encouraged and welcomed as the sky is NOT FALLING IMO. Profitability comes by Spring of 2017 – ahead of schedule!!
- This OTC ticker has a proven winner at the helm in Dr. D, is cash flow positive, and has a major game-changing product ready for approval which can happen any day now. IF You ain’t in when positive news hits, you likely miss dollar-land people with a potential buyout inside of 2 years.
* GLTA and try some products (order online) – they WORK ! Also, review post #39 and please do your part
(2)
(0)Innovus Pharmaceuticals Inc. (INNV) Stock Research Links
Scroll down for more posts ▼